7.1 Pharmacotherapy of Central Nervous System Infections

Blood-Brain Barrier Physiology and Antimicrobial Penetration Pharmacokinetics

Pharmacotherapy of central nervous system (CNS) infections presents distinct challenges due to the restrictive anatomical and biochemical barriers safeguarding the brain. The blood-brain barrier (BBB)—formed by brain microvascular endothelial cells interconnected by complex continuous tight junctions (zonula occludens composed of claudins, occludins, and junctional adhesion molecules) enveloped by pericytes and astrocytic end-feet (glia limitans)—and the blood-cerebrospinal fluid barrier (BCSFB) at the choroid plexus epithelium restrict passive paracellular movement of solutes.

Active efflux pumps expressed at the luminal and abluminal endothelial membranes, particularly P-glycoprotein (ABCB1) and multidrug resistance-associated proteins (MRPs), actively transport lipophilic xenobiotics (such as macrolides, fluoroquinolones, and HIV protease inhibitors) out of the brain parenchyma back into the capillary lumen.

Physicochemical Determinants of CNS Penetration

Penetration of an antimicrobial into the cerebrospinal fluid (CSF) and brain interstitium depends on several key properties:

1. Molecular Weight and Size: Small molecules (<400–500 Da) diffuse across membranes far more effectively than bulky molecules (e.g., vancomycin, polymyxins, daptomycin, and echinocandins achieve lower baseline CSF penetration).
2. Lipophilicity: Uncharged, lipid-soluble molecules (e.g., metronidazole, rifampin, linezolid, chloramphenicol, and fluoroquinolones) readily pass across intact lipid bilayers, achieving high CSF-to-serum area under the curve (AUC) ratios (often 50–100%) even in the absence of meningeal inflammation.
3. Plasma Protein Binding: Only the unbound (free) fraction of drug in serum is thermodynamically available to cross the BBB. Ceftriaxone is approximately 85–95% bound to serum albumin; however, its high absolute daily dosing ensures adequate free drug concentrations in CSF. In contrast, drugs with near-complete protein binding (e.g., daptomycin, teicoplanin) exhibit limited CSF penetration.
4. Ionization State at Physiological pH: Non-ionized fractions penetrate lipid membranes substantially faster than charged molecules.
5. Meningeal Inflammation: In acute purulent meningitis, leukocyte transmigration and bacterial exotoxins disrupt endothelial tight junctions, de-repress paracellular pores, and downregulate active efflux transporters. This markedly enhances the entry of polar, hydrophilic beta-lactams and glycopeptides. However, as antimicrobial therapy resolves the inflammation and tight junctions re-form, CSF penetration declines. For this reason, aggressive high-dose bactericidal regimens must be maintained throughout the entire treatment course.

---

Acute Community-Acquired Bacterial Meningitis

Clinical Presentation and Diagnostic Lumbar Puncture

The classic clinical triad of acute bacterial meningitis consists of fever, nuchal rigidity (neck stiffness), and altered mental status. While only 44–66% of adult patients present with all three findings simultaneously, virtually all patients (>95%) exhibit at least two of the following four signs: fever, headache, stiff neck, and altered mentation. Physical exam maneuvers such as Kernig's sign (pain/resistance upon passive knee extension with the hip flexed at 90°) and Brudzinski's sign (involuntary hip and knee flexion upon passive neck flexion) possess high specificity (>95%) but poor sensitivity (<10%), meaning their absence never excludes acute meningitis.

Evaluation mandates immediate lumbar puncture (LP) with cerebrospinal fluid analysis, unless contraindicated by risk factors for brain herniation.

Suspected Acute Bacterial Meningitis
                │
                ▼ Screening for Screening Criteria:
  - Immunocompromised state (HIV, chemotherapy, post-transplant)
  - History of CNS disease (mass, stroke, focal infection)
  - New-onset seizure within previous 7 days
  - Papilledema on fundoscopic examination
  - Focal neurological deficit (e.g., hemiparesis, dilated pupil)
  - Severely altered sensorium / Glasgow Coma Scale < 10
                │
       ┌────────┴────────┐
      YES               NO
       │                 │
       ▼                 ▼
  1. Draw Blood Cultures   Immediate Lumbar Puncture
  2. Administer Empiric    prior to antibiotics
     Antibiotics +
     Dexamethasone
  3. Urgent CT Head
  4. Perform LP if CT
     shows no mass effect

Cerebrospinal Fluid Differentiation

Age- and Risk-Stratified Empiric Pharmacotherapy

Pathogens responsible for acute community-acquired bacterial meningitis distribute predictably across patient age brackets and comorbid conditions:

1. Neonates (<1 month):
   • Microbiology: Streptococcus agalactiae (Group B Streptococcus [GBS]), Escherichia coli (K1 capsular antigen strains), and Listeria monocytogenes.
   • Empiric Regimen: Ampicillin (150–300 mg/kg/day divided every 6–8 hours) PLUS Cefotaxime (100–200 mg/kg/day divided every 6–8 hours) OR Ampicillin PLUS Gentamicin.
   • Clinical Pearl: Ceftriaxone is strictly contraindicated in neonates. Ceftriaxone displaces bilirubin from human serum albumin, precipitating kernicterus (bilirubin encephalopathy), and co-precipitates with intravenous calcium salts in neonatal lungs and kidneys, causing microvascular thromboembolism and fatal end-organ failure. Cefotaxime lacks this high-affinity albumin displacement and is the cephalosporin of choice in neonates.
2. Infants, Children, and Adults (1 month to 50 years):
   • Microbiology: Streptococcus pneumoniae (lancet-shaped Gram-positive diplococci) and Neisseria meningitidis (Gram-negative diplococci).
   • Empiric Regimen: Vancomycin (15–20 mg/kg IV every 8–12 hours, targeting an AUC/MIC of 400–600 mg*h/L or trough 15–20 mcg/mL) PLUS Ceftriaxone (2 g IV every 12 hours) or Cefotaxime (2 g IV every 4–6 hours).
3. Adults >50 years, Immunocompromised Patients, Alcohol Use Disorder, Chronic Liver Disease, or Pregnancy:
   • Microbiology: Streptococcus pneumoniae, Neisseria meningitidis, Listeria monocytogenes (facultative intracellular Gram-positive bacillus), and aerobic Gram-negative bacilli (E. coli, Klebsiella pneumoniae).
   • Empiric Regimen: Vancomycin PLUS Ceftriaxone (2 g IV every 12 hours) PLUS Ampicillin (2 g IV every 4 hours).
   • Clinical Pearl: Cephalosporins (including 3rd, 4th, and 5th generation agents) possess zero antimicrobial activity against Listeria monocytogenes due to intrinsic lack of binding affinity for penicillin-binding protein 3 (PBP3). Therefore, ampicillin must be added to provide bactericidal coverage.
4. Severe Beta-Lactam Allergy (Anaphylaxis, Angioedema):
   • Regimen: Vancomycin (15–20 mg/kg IV q8–12h) PLUS Moxifloxacin (400 mg IV q24h) or Levofloxacin (500 mg IV q12h) PLUS Trimethoprim-Sulfamethoxazole (TMP-SMX, 5 mg/kg IV every 6–8 hours based on the TMP component for Listeria coverage).
   • Alternative: High-dose Meropenem (2 g IV every 8 hours) can be employed if the reaction was a non-IgE-mediated mild rash, as cross-reactivity between penicillins and carbapenems is <1%. However, meropenem has lower bactericidal activity against Listeria compared to ampicillin or TMP-SMX.

Targeted Pathogen-Directed Antimicrobial Therapy

Once cerebrospinal fluid cultures and antimicrobial susceptibility testing (AST) results return, therapy must be rapidly de-escalated:

• Streptococcus pneumoniae (Duration: 10–14 days):
  • Penicillin-susceptible (MIC ≤ 0.06 mcg/mL): Penicillin G (4 million units IV every 4 hours) or Ampicillin (2 g IV every 4 hours).
  • Ceftriaxone-susceptible (Ceftriaxone MIC ≤ 0.5 mcg/mL): Ceftriaxone 2 g IV every 12 hours.
  • Ceftriaxone-resistant (Ceftriaxone MIC ≥ 1.0 mcg/mL): Maintain combination therapy with Vancomycin PLUS Ceftriaxone. Add oral/IV Rifampin (600 mg daily) if the patient exhibits clinical deterioration or if vancomycin penetration is compromised by corticosteroid use.
• Neisseria meningitidis (Duration: 7 days):
  • Ceftriaxone 2 g IV every 12 hours. If confirmed penicillin-susceptible (MIC < 0.1 mcg/mL), Penicillin G (4 million units IV every 4 hours) can be used.
  • Droplet Isolation: Maintain for the first 24 hours of effective antimicrobial therapy.
  • Post-Exposure Chemoprophylaxis: Indicated for close household contacts, daycare contacts, or healthcare providers with direct exposure to oral secretions (e.g., endotracheal intubation): Rifampin 600 mg PO twice daily for 2 days (4 doses total; colors secretions orange, induces CYP3A4, inactivates oral contraceptives); Ceftriaxone 250 mg IM single dose (preferred in pregnancy); or Ciprofloxacin 500 mg PO single dose.
• Listeria monocytogenes (Duration: ≥ 21 days):
  • Ampicillin 2 g IV every 4 hours (or Penicillin G 4 million units IV every 4 hours) PLUS optional synergistic Gentamicin (1–1.7 mg/kg IV every 8 hours) for the initial 7–10 days.
  • Minimum duration is 21 days, extending to 4–6 weeks for patients with cerebritis, rhombencephalitis (brainstem infection), or severe immunosuppression.

---

Adjunctive Corticosteroid Therapy: Dexamethasone Protocol

Pathophysiological Rationale

Antimicrobial-induced bacterial lysis releases high concentrations of immunogenic cell-wall components—including peptidoglycan polymers, teichoic acid, and endotoxins (lipopolysaccharide)—into the subarachnoid space. This debris stimulates microglia, astrocytes, and perivascular macrophages via Toll-like receptors (TLR2 and TLR4), releasing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, and platelet-activating factor).

This secondary inflammatory cascade drives neutrophil recruitment, blood-brain barrier disruption, vasogenic and cytotoxic cerebral edema, elevation of intracranial pressure (ICP), reduction in cerebral perfusion pressure (CPP), cortical ischemia, and oxidative destruction of the organ of Corti in the cochlea, resulting in permanent sensorineural hearing loss.

Intravenous Bactericidal Antimicrobial Administration
                     │
                     ▼ Rapid Lysis of S. pneumoniae
Liberation of Peptidoglycan, Teichoic Acid, and Pneumolysin
                     │
                     ▼ Subarachnoid Space Cytokine Storm
      [Massive release of TNF-alpha, IL-1beta, and Matrix Metalloproteinases]
                     │
       ┌─────────────┴─────────────┐
       ▼                           ▼
Endothelial Tight Junction     Cochlear Hair Cell Toxicity
Degradation & Cerebral Edema                │
       │                           ▼
       ▼                 Sensorineural Hearing Loss
Elevated Intracranial Pressure
       │
       ▼
Brain Herniation & Death

==> Suppressed by Adjunctive Dexamethasone Administered Prior to Antibiotics!

Clinical Evidence and Administration Protocol

The landmark European Dexamethasone Study (de Gans and van de Beek, NEJM 2002) evaluated 301 adults with acute bacterial meningitis randomized to receive adjunctive dexamethasone versus placebo:

• Dexamethasone significantly reduced unfavorable outcomes (RR 0.59, 95% CI 0.37–0.94) and overall mortality (7% vs 15%, p=0.04).
• In the subgroup with confirmed Streptococcus pneumoniae, mortality was reduced from 34% in the placebo group to 14% in the dexamethasone group (p=0.006), with significant reductions in sensorineural hearing loss and long-term neurological disability.

Pharmacokinetic Interactions with Glycopeptides

Dexamethasone stabilizes endothelial tight junctions and attenuates meningeal inflammation. As a secondary effect, it decreases the penetration of vancomycin into the CSF by up to 30–50%. To prevent clinical failure in cephalosporin-resistant pneumococcal meningitis:

• Maintain aggressive vancomycin dosing (15–20 mg/kg IV every 8–12 hours) targeting upper-range trough concentrations (15–20 mcg/mL) or an AUC/MIC ≥ 400.
• In patients with highly resistant pneumococcal strains (ceftriaxone MIC ≥ 1.0 mcg/mL) receiving concurrent dexamethasone, add Rifampin (600 mg IV/PO daily), which achieves outstanding CSF penetration independent of meningeal inflammation.

---

Healthcare-Associated Ventriculitis and Meningitis (HCAVM)

Epidemiology and Microbiology

Healthcare-associated ventriculitis and meningitis occurs secondary to invasive neurosurgical interventions, penetrating head trauma, or indwelling cerebrospinal fluid diversion hardware, notably external ventricular drains (EVDs), ventriculoperitoneal (VP) shunts, and intracranial pressure (ICP) monitoring transducers. The risk of EVD infection escalates with catheter duration, CSF leak, and frequent catheter irrigation or sampling.

Microbiology differs markedly from community-acquired cases:

1. Coagulase-Negative Staphylococci (CoNS): Staphylococcus epidermidis accounts for 40–50% of shunt infections. It produces polysaccharide intercellular adhesin (PIA), forming robust multidrug-tolerant biofilms on synthetic silicon catheters.
2. Staphylococcus aureus: Accounts for 15–20% of cases, with a high proportion of methicillin-resistant S. aureus (MRSA).
3. Cutibacterium acnes: An anaerobic, slow-growing skin commensal that causes indolent, late-presenting VP shunt infections with minimal pleocytosis. Diagnostic cultures require extended anaerobic incubation for up to 14 days.
4. Aerobic Gram-Negative Bacilli: Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Enterobacter cloacae complex.

Empiric Systemic Pharmacotherapy

In accordance with Infectious Diseases Society of America (IDSA) guidelines, empiric therapy for suspected healthcare-associated ventriculitis mandates:

• Vancomycin (15–20 mg/kg IV every 8–12 hours, targeting trough 15–20 mcg/mL) PLUS an anti-pseudomonal beta-lactam:
  • Cefepime (2 g IV every 8 hours) OR
  • Ceftazidime (2 g IV every 8 hours) OR
  • Meropenem (2 g IV every 8 hours; preferred if multidrug-resistant or ESBL/AmpC-producing organisms are prevalent).

Source Control and Hardware Removal

Eradication of foreign-body CNS infection without hardware removal is rarely achievable due to bacterial persistence within sheltered biomaterial biofilms. Successful therapy requires complete removal or externalization of the infected VP shunt or EVD, paired with temporary external drainage. Reimplantation of a new permanent shunt should be delayed until CSF cultures have been sterile for at least 7 to 10 days for virulent pathogens, or 3 days for CoNS with normal CSF biochemistry.

Intraventricular and Intrathecal Antimicrobial Therapy

When ventriculitis fails to clear despite optimized systemic intravenous therapy, when foreign hardware cannot be immediately removed, or when caused by extreme drug-resistant (XDR) pathogens (such as carbapenem-resistant Acinetobacter baumannii [CRAB] or MDR Pseudomonas aeruginosa) where systemic antimicrobials achieve sub-inhibitory CSF concentrations, direct intraventricular (IVT) or intrathecal (IT) antimicrobial instillation is indicated.

Indications for Intraventricular / Intrathecal Antimicrobial Delivery:
1. Refractory ventriculitis with persistently positive CSF cultures on IV therapy
2. Infection caused by multidrug-resistant (MDR/XDR) Gram-negative bacilli
3. High-level glycopeptide or aminoglycoside systemic toxicity risk
4. Retention of colonized hardware that cannot be surgically explanted

Administration Technique: Reconstitute the preservative-free agent in 2–5 mL of preservative-free 0.9% sodium chloride. Inject via the EVD port, then clamp the ventricular drain for 30 to 60 minutes to allow homogeneous drug diffusion throughout the ventricular system and third/fourth ventricles before re-opening the drain to avoid premature medication clearance.

---

Viral Encephalitis and Aseptic Meningitis

Clinical Distinction: Encephalitis versus Meningitis

A clear clinical boundary separates meningitis from encephalitis:

• Aseptic (Viral) Meningitis: Inflammation is restricted to the meninges. Patients manifest with headache, fever, photophobia, and neck stiffness, but cerebral parenchymal function remains entirely preserved (no confusion, no aphasia, no focal motor deficits).
• Viral Encephalitis: Direct parenchymal infection and inflammation. Hallmarks include altered mental status, personality or behavioral changes, delirium, confusion, focal motor/sensory deficits, cranial neuropathies, and new-onset focal seizures.

Herpes Simplex Virus Type 1 (HSV-1) Encephalitis

HSV-1 is the most common cause of non-epidemic, sporadic, fatal viral encephalitis in immunocompetent adults (>90% of cases; HSV-2 primarily causes neonatal encephalitis and benign recurrent lymphocytic meningitis [Mollaret's meningitis]).

• Pathogenesis: Latent virus in the trigeminal ganglion or olfactory bulb undergoes reactivation and spreads retrogradely into the medial temporal and inferior frontal lobes, inducing asymmetric, liquefactive, hemorrhagic necrotizing encephalitis.
• Diagnostic Hallmarks:
  • Lumbar Puncture: Lymphocytic pleocytosis (50–500 WBC/mcL), elevated erythrocytes (reflecting parenchymal hemorrhagic necrosis), elevated protein, and normal glucose.
  • Molecular Testing: CSF HSV polymerase chain reaction (PCR) is the gold standard diagnostic (sensitivity >95%, specificity >98%). However, CSF drawn during the initial 24–48 hours of illness may yield a false-negative result. If clinical suspicion remains high despite a negative early PCR, acyclovir must be continued and the LP repeated in 3 to 7 days.
  • Neuroimaging (MRI): T2/FLAIR hyperintensity with diffusion restriction and edema localized characteristically to the unilateral or asymmetric temporal lobes, insular cortex, and orbital surfaces of the frontal lobes.
• Pharmacotherapy:
  • High-Dose Intravenous Acyclovir: 10 mg/kg IV every 8 hours.
  • Dosing Weight: Must be calculated using Ideal Body Weight (IBW) in overweight or obese patients to avoid overexposure and severe nephrotoxicity.
  • Duration: 14 to 21 days (immunocompromised patients require a full 21 days with documentation of negative repeat CSF PCR before discontinuation).
  • Toxicity Mitigation: Acyclovir has poor aqueous solubility at neutral physiological pH. Rapid bolus infusions cause acyclovir crystal nephropathy, characterized by insoluble needle-shaped intratubular birefringent crystal precipitation, direct mechanical tubular obstruction, and oliguric acute kidney injury. Prevent by infusing each dose slowly over at least 1 hour and co-administering intravenous crystalloid maintenance hydration (e.g., normal saline at 75–125 mL/hr).

Other Viral Pathogens

• Varicella-Zoster Virus (VZV): Manifests as encephalitis, cerebellitis, or post-herpetic cerebral vasculopathy (triggering acute ischemic stroke). Treated with IV Acyclovir 10–15 mg/kg every 8 hours for 10–14 days, frequently combined with a short pulse of corticosteroids for vasculopathy.
• Enteroviruses (Coxsackieviruses, Echoviruses): Account for >80–90% of all viral meningitis cases, peaking in summer and autumn. Pathogenesis involves enteric viral replication followed by viremia. Diagnosis is confirmed via CSF enteroviral RT-PCR. Management is primarily supportive; pleconaril and intravenous immunoglobulin (IVIG) are reserved for life-threatening neonatal enteroviral sepsis.

---

Intracranial Space-Occupying Infections: Brain Abscess and Subdural Empyema

Pathogenesis and Microbiology

Intracranial brain abscesses develop through three distinct pathophysiological mechanisms:

1. Contiguous Spread (40–50% of cases): Direct extension from chronic suppurative otitis media or mastoiditis (localizing to the temporal lobe or cerebellum), paranasal sinusitis (localizing to the frontal lobe), or odontogenic infections.
2. Hematogenous Dissemination (25–35% of cases): Embolic seeding from distant septic foci, commonly associated with right-to-left cardiac shunts (e.g., cyanotic congenital heart disease, patent foramen ovale), pulmonary arteriovenous malformations (Hereditary Hemorrhagic Telangiectasia / Osler-Weber-Rendu syndrome), bronchiectasis, or infective endocarditis. These lesions characteristically present as multiple discrete abscesses at the gray-white matter junction in the distribution of the middle cerebral artery.
3. Post-Neurosurgical or Penetrating Trauma (10–15% of cases): Direct inoculation of scalp and skin flora.

Brain abscesses are overwhelmingly polymicrobial:

• Streptococci: Oral viridans streptococci and particularly the Streptococcus anginosus (milleri) group (S. anginosus, S. intermedius, S. constellatus), which elaborate hyaluronidase and hydrolytic toxins promoting tissue liquefaction and encapsulation.
• Obligate Anaerobes: Fusobacterium nucleatum, Prevotella species, Bacteroides fragilis, Peptostreptococcus.
• Staphylococcus aureus: Predominant in penetrating trauma, neurosurgical procedures, or hematogenous infective endocarditis.
• Enterobacterales and Pseudomonas: Common in chronic otogenic spread or nosocomial post-craniotomy collections.

Pharmacotherapy and Neurosurgical Source Control

Optimal management requires the integration of surgical decompression and targeted antimicrobials:

Suspected Brain Abscess on Contrast-Enhanced MRI
                      │
          ┌───────────┴───────────┐
          ▼                       ▼
Lesion >= 2.5 cm, Mass Effect,    Small Lesion (< 2.0-2.5 cm),
Midline Shift, or Impending       Surgically Inaccessible (Deep/Brainstem),
Ventricular Rupture               No Impending Herniation
          │                               │
          ▼                               ▼
Neurosurgical Stereotactic        Empiric Antimicrobial Therapy:
Needle Aspiration / Excision      - Ceftriaxone 2 g IV q12h
  - Send pus for Gram stain,      - Metronidazole 500 mg IV q6-8h
    aerobic/anaerobic cultures,   - Vancomycin 15-20 mg/kg IV q8-12h
    and fungal/mycobacterial PCR          │
          │                               ▼
          ▼                       Serial Neuroimaging (MRI) every
Targeted Antimicrobials x 4-6 wk  1-2 weeks to verify size reduction

• Empiric Regimen:
  • Ceftriaxone (2 g IV every 12 hours) PLUS Metronidazole (500 mg IV every 6–8 hours) PLUS Vancomycin (15–20 mg/kg IV every 8–12 hours).
  • Why Metronidazole is Indispensable: Metronidazole demonstrates superior penetration across both the blood-brain barrier and the thick collagenous capsule of brain abscesses, retaining unhindered bactericidal activity within the acidic, hypoxic, necrotic abscess core where aminoglycosides, macrolides, and beta-lactams are often impaired.
  • Otogenic or Nosocomial Adjustment: If chronic mastoiditis, otitis media, or prior neurosurgery is the source, replace Ceftriaxone with Cefepime (2 g IV every 8 hours) or Meropenem (2 g IV every 8 hours) to ensure broad Pseudomonas aeruginosa coverage.
• Duration of Therapy:
  • Surgically aspirated or excised abscesses: 4 to 6 weeks of intravenous therapy.
  • Medically treated abscesses (no aspiration): 6 to 8 weeks minimum.
  • Monitor response with serial contrast-enhanced MRI scans every 2 weeks until complete radiographic resolution of the ring-enhancing rim.